Newsletter

069620 - Daewoong Pharma

069620 Summary
Biopharma
Stock Price & Overview
₩116,100 +1,300 (+1.13%) Close · Sep 4, 2026 KST
KOSPI | ₩KRW | Close: ₩116,100  ≈ US$83  ·  Market cap ₩1.3tn (≈ $961m)
Why this page exists. Korean issuers file to DART, not the SEC, and almost nothing is published in English. Titles here are translated; where kstock has read the filing, the row carries the explanation and the amount in won and dollars. How we pick »

069620 DART Filings

DART

Debt guarantee for a third party

Filing09/04/26title translated
DART

Litigation Filed

Legal09/02/26title translated
DART

Proxy solicitation reference document

Filing08/25/26title translated
DART

Notice of general meeting of shareholders

Filing08/25/26title translated
DART

Half-Year Report

Periodic08/14/26title translated
DART

Preliminary operating results (fair disclosure)

Filing07/29/26title translated
DART

Resolution to convene a general meeting of shareholders

Filing07/28/26title translated
DART

Record date set, shareholder register closed

Filing07/28/26title translated
DART

Material matter affecting investment judgment

Filing07/10/26title translated
DART

New Facility Investment

Capex06/30/26title translated
DART

Sustainability report (voluntary)

Filing06/30/26title translated
DART

Single Supply Contract Signed

Contract06/26/26title translated
DART

Material matter affecting investment judgment

Filing06/23/26title translated
DART

Corporate governance report

Filing06/01/26title translated
DART

Material matter affecting investment judgment

Filing05/26/26title translated
DART

Material matter affecting investment judgment

Filing05/26/26title translated
DART

Material matter affecting investment judgment

Filing05/21/26title translated
DART

Material matter affecting investment judgment

Filing05/20/26title translated
DART

Quarterly Report

Periodic05/15/26title translated
DART

Material matter affecting investment judgment

Filing05/12/26title translated
DART

Preliminary operating results (fair disclosure)

Filing05/12/26title translated
DART

Material matter affecting investment judgment

Filing05/07/26title translated
2 routine filings (insider holdings reports, IR schedules)DART

Insider / Major Shareholder Holdings Report

Ownership08/21/26title translated
DART

Insider / Major Shareholder Holdings Report

Ownership07/07/26title translated
24 filings on file, grouped where one event produced many. Source: DART, operated by Korea's Financial Supervisory Service.

Similar to 069620

SymbolLast Price
068760Celltrion Pharm, Inc.₩40,850
+0.0%
007390Naturecell Co., Ltd.₩23,950
+0.2%
006280GC Biopharma Corp.₩127,600
+0.5%
950160Kolon Tissue Gene, Inc.₩17,100
+1.1%
039200Oscotec, Inc.₩36,600
+1.9%
290650L & C BIO Co., Ltd.₩47,900
-1.4%
127120JS Link₩33,600
+12.4%
475830Orum Therapeutics, Inc.₩55,900
+2.6%
195940HK inno.N Corporation₩42,050
+0.7%
003090Daewoong Co., Ltd.₩16,860
-2.0%
Compare all 48 in Biopharma

What a US investor should know

  • Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
  • Daily limitKorean stocks can move at most ±30% in a session before trading halts.
  • Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
  • ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.